Navigation Links
Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b

Helix BioPharma Corp.

AURORA, ON, March 30, 2007 /PRNewswire-FirstCall/ - Helix today announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus (HPV) induced low-grade cervical lesions.

The study showed a clinically efficacious response to treatment in nearly half of the treated patients. In addition, the product demonstrated an excellent safety profile, with no significant local intolerance or drug-related serious adverse event observations.

"Treated patients responded well, both in terms of efficacy and safety to this new investigational therapeutic," said Prof. Dr. med. Achim Schneider M.P.H., a world expert in the field of cervical cancer and Director of the Department of Gynaecology at the Charite University Hospital in Berlin. "Helix's product shows real promise as a practical and effective pharmaceutical means of preventing cervical cancer development in women presenting with HPV-induced cervical lesions", continued Prof. Schneider.

About the Clinical Study

A total of 41 women with cytologically confirmed, HPV-induced low-grade squamous intraepithelial lesions (LSIL) of the cervix were studied across four sites in Germany. Twenty women received Topical Interferon Alpha-2b, self-administered intravaginally three times per week for a period of 6 weeks with a follow-up evaluation at 12 weeks, compared with 21 separately studied women who received no treatment whatsoever over the same study period.

The primary endpoint and main outcome for both groups was the Pap-response rate defined as the proportion of patients with resolution of their abnormal Pap smear LSIL cytology to normal during the 12 week study duration. Pap smear normalization was considered to occur if the patient's Pap smear improved to group II or better from any of Pap smear groups IIW through IIID as per the common European stan
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
8. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
9. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
10. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:10/1/2014)... Texas , Oct. 1, 2014 ... is scaling volume production of photoactive quantum dots ... technologies . While offering numerous advantages for solar ... producing large quantities of quantum dots with which ... now kept them from commercial utilization and acceptance. ...
(Date:10/1/2014)... , Oct. 1, 2014 ... a clinical-stage biopharmaceutical company focused on cardio-renal, ... results from its 371 patient Phase 2b ... constipation-predominant irritable bowel syndrome (IBS-C).  Results from ... meaningful improvement in IBS-C symptoms for tenapanor-treated ...
(Date:10/1/2014)... Switzerland , October 1, 2014 /PRNewswire/ ... Clinical Genomics and Next Generation Sequencing (NGS) data analysis, ... to run full cystic fibrosis analysis in a single ... and characterisation of all types of variants in a ... Until now, it has not been possible to ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... raise your risk for high blood pressure, a new study ... lived within 109 yards of a busy road had a ... women living at least half a mile away, researchers report. ... of our physical environment on our health and well-being," said ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) -- ... may face an increased risk of dying in the next several ... older Americans, researchers found those who were unable to detect scents ... as likely to die in the next five years, versus those ... the inability to distinguish odors -- was a bigger predictor of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... have a total of 500 confirmed cases of Enterovirus D68, ... since the summer, U.S. health officials reported Wednesday. Four ... but it,s not clear what role -- if any -- ... officials are also trying to determine if the virus is ...
(Date:10/1/2014)... University of Adelaide have developed a model that could ... outcome from treatment - from their very first psychotic ... of factors, including clinical symptoms, cognitive abilities, MRI scans ... blood. , Speaking in the lead up to World ... Psychiatry , Professor Bernhard Baune , says ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Predicting the future course of psychotic illness 2Health News:Eighty percent of bowel cancers halted with existing medicines 2
... citrus fruits rich in Vitamin C such as papaya, oranges ... research has found that the nutrient could help reduce ... ,Researchers from the University of Warwick have found that the ... in diabetics. ,Free radicals are tissue-damaging molecules, and ...
... and smoke-free work environment play key roles in helping people ... a study has found. ,The study was ... environmental factors are more influential than individual behaviours and beliefs ... researcher Jon Macy, said that though smoking cessation attempts often ...
... , ... ... ... clutches? Even fetuses in wombs experience stress! Stress can stem from a variety of causes-relationships, job, school and daily activities-just about anything. ...
... Working in an environment where smoking is allowed is especially ... that is not considered safe at any level, a ... by researchers at the Multnomah County Health Department and Oregon ... elevated levels of the carcinogen NNK, which is found in ...
... led by a Children's Hospital of Eastern Ontario (CHEO )researcher ... to vitamin D deficiency Rickets. Despite the fact that generation ... supplements and sunshine, vitamin D deficiency rickets has persisted in ... disease that weakens the leg bones and stunts growth, the ...
... death rates for men from the rural areas are 10 ... ,Despite The fact that cancer survival rates are improving overall, ... death rate of men living in rural areas and their ... in Australia has risen from 78,857 new cases in 1996 ...
Cached Medicine News:Health News:Smoke-free Workplace, Non-smoking Spouse Help Quitters Stay Off the Butt 2Health News:Living With Stress 2Health News:Living With Stress 3Health News:Living With Stress 4Health News:Secondhand Workplace Smoke Hits Non-smokers Badly 2Health News:Vitamin D Deficiency Still Persists in Babies 2Health News:Cancer Deaths of Rural Men on the High 2
... The Repeater Pipette* provides quick, convenient, ... procedures. Eppendorf Combitips have a polyethylene ... them ideal for use with most ... Product features: Five separate volumes can ...
... The only catheter of its kind, ... rapidly collects real-time cardiac electrical information, ... map. With 64 electrodes, this unique ... more than 3,000 points of electrical ...
... St. Jude Medical's universal programmer platform, ... used in combination with St. Jude ... products for emerging indications. Features ... touch-sensitive, active matrix LCD screen Programmer ...
... Coronary Stent System introduces ... lesion access and conformability. ... low crossing profile, and ... the performance of the ...
Medicine Products: